AllSci News
Fosun Pharma secures USD 60m option on AriBio's PDE5 inhibitor for Alzheimer's disease
Fosun Pharma's subsidiary has committed USD 60 million upfront to secure an exclusive option over the global rights to AR1001, a Phase III oral PDE5...
BridgeBio files NDA for encaleret in rare calcium disorder with no approved therapy
An NDA submission for a first-in-indication oral therapy positions encaleret as a potential alternative to a standard of care that has remained unchanged...
Daiichi Sankyo's three imminent regulatory decisions and next-generation platforms reshape growth trajectory
Daiichi Sankyo's Q4 2026 earnings call on May 11, 2026 revealed three converging regulatory decisions — for Enhertu (trastuzumab deruxtecan), Datroway...
Pfizer terminates Phase I trial of anti-CD25 ADC PF-08046032 in oncology
Pfizer's Phase I program for PF-08046032, an anti-CD25 antibody-drug conjugate designed to deplete immunosuppressive regulatory T cells within the tumor...
Restore Vision's optogenetic gene therapy restores light perception in end-stage retinitis pigmentosa patients
Interim data from a GPCR-based optogenetic gene therapy add early human evidence to a mutation-agnostic approach for end-stage retinitis pigmentosa, a...
CDT Equity advances patent strategy for AZ-acquired myeloperoxidase inhibitor for male infertility
CDT Equity Inc. (Nasdaq: CDT), headquartered in Naples, Florida, has advanced AZD5904, a selective myeloperoxidase (MPO) inhibitor originally licensed from AstraZeneca, into…
European Commission approves Pfizer’s Hympavzi for hemophilia A and B patients with inhibitors
The European Commission has approved Pfizer’s Hympavzi (marstacimab) for hemophilia A and B patients with inhibitors. The approval means Pfizer is one…
PharmAla Biotech forms Restora Neurosciences SPV with Aluvaris for MDXX clinical development
PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF), Toronto, has structured a special purpose vehicle to advance APA-01, a patented pre-IND MDXX-class small...
Whitehawk Therapeutics raises USD 87.5m in private placement to extend ADC runway through 2028
A clinical-stage antibody drug conjugate company is extending its cash runway into the second half of 2028 through a USD 87.5 million private placement,...
Actuate Therapeutics' oral GSK-3β inhibitor elraglusib set for first trials in advanced solid tumors
A shift from intravenous to oral administration marks the next phase of Actuate Therapeutics' (Nasdaq: ACTU) elraglusib program, after the Chicago- and Fort...
Delos Capital and AP Biosciences launch venture creation platform for next-generation antibodies
A venture creation model combining biologics discovery with company-building infrastructure positions AP Biosciences to extend its antibody platforms beyond its internal pipeline,…
AndzonBio2 taps up Cambridge Uni’s ALBORADA institute for neuroinflammatory drug discovery
A Paris-based neuroscience company is gaining access to one of the UK’s leading academic drug discovery platforms, focused on neuroinflammation as a…
Collegium acquires Azstarys from Corium Therapeutics for USD 650m plus contingent payments
Collegium Pharmaceutical (Nasdaq: COLL), headquartered in Stoughton, Massachusetts, has completed the acquisition of Azstarys (serdexmethylphenidate and...
Akari Therapeutics secures European patent for Thailanstatin analog ADC payload platform
A European composition-of-matter patent covering a novel class of RNA splicing modulator payloads extends intellectual property protection for Akari Therapeutics’ antibody-drug conjugate…
Oxcia AB secures Canadian patent for OXC-201 ahead of Phase I in IPF
Oxcia AB (Sweden), a clinical-stage company focused on oxidative DNA damage and DNA Damage Response (DDR) biology, has received Canadian patent approval…
The AllSci Brief
Free, systematic R&D and deal news. Daily.